SCHEMBL1820481

SCHEMBL1820481

CC(C(=O)O)c1ccc(Nc2nc(C(F)(F)F)cs2)cc1

nearest known ligand 0.51

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
FFAR2 O15552 1/20 0.51
GAA P10253 3/20 0.50
NPC1 O15118 1/20 0.50
ALDH1A1 P00352 1/20 0.50
MAPT P10636 1/20 0.50
NFKB1 P19838 1/20 0.50
RAB9A P51151 1/20 0.50
NFKB2 Q00653 1/20 0.50
RELA Q04206 1/20 0.50
CCR4 P51679 1/20 0.47
ALPL P05186 1/20 0.44
ALPI P09923 1/20 0.44
CFTR P13569 1/20 0.42
MGLL Q99685 1/20 0.41
FAAH O00519 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2185845 1.00 FFAR2 (0.51) FFAR2GAANPC1ALDH1A1MAPT
SCHEMBL262464 1.00 FFAR2 (0.51) FFAR2GAANPC1ALDH1A1MAPT
SCHEMBL2185593 0.99 FFAR2 (0.50) FFAR2GAANPC1ALDH1A1MAPT
SCHEMBL27818106 0.99 FFAR2 (0.50) FFAR2GAANPC1ALDH1A1MAPT
SCHEMBL262345 0.91 FFAR2 (0.47) FFAR2GAANPC1ALDH1A1MAPT
SCHEMBL2303876 0.90 FFAR2 (0.51) FFAR2GAANPC1ALDH1A1MAPT
SCHEMBL2303870 0.90 FFAR2 (0.51) FFAR2GAANPC1ALDH1A1MAPT
SCHEMBL262169 0.90 FFAR2 (0.51) FFAR2GAANPC1ALDH1A1MAPT
SCHEMBL15402199 0.90 FFAR2 (0.49) FFAR2GAANPC1ALDH1A1MAPT
SCHEMBL2183898 0.90 FFAR2 (0.49) FFAR2GAANPC1ALDH1A1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 116 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4686469-A1 CXCL8 INHIBITORS FOR USE IN THE TREATMENT OF DIABETES-ASSOCIATED COMORBIDITIES Dompé farmaceutici SpA (IT) 2026-02-04 EP claimed
EP-4686472-A1 CXCL8 INHIBITORS FOR USE IN THE TREATMENT OF OCULAR GRAFT-VERSUS-HOST DISEASE Dompé farmaceutici SpA (IT) 2026-02-04 EP claimed
EP-4678171-A1 SYSTEMICALLY-ADMINISTERED CXCL8 INHIBITORS FOR USE IN THE PREVENTION OR TREATMENT OF OCULAR MUCOUS MEMBRANE PEMPHIGOID AND/OR ORAL MUCOUS MEMBRANE PEMPHIGOID Dompé farmaceutici SpA (IT) 2026-01-14 EP claimed
EP-3518898-B1 PREVENTION AND TREATMENT OF DIABETIC NEPHROPATHY CHILDRENS MEDICAL CT CORP (US) 2025-12-17 EP claimed
EP-4646193-A1 CXCL8 INHIBITORS FOR USE IN THE TREATMENT OF OCULAR MUCOUS MEMBRANE PEMPHIGOID AND/OR ORAL MUCOUS MEMBRANE PEMPHIGOID Dompé farmaceutici S.p.A. (IT) 2025-11-12 EP claimed
EP-4563594-A1 CXCL8 INHIBITORS FOR USE IN THE TREATMENT OF TUMORS WITH LOW STROMAL CAV1 LEVELS Dompe' Farmaceutici SpA (IT) 2025-06-04 EP claimed
US-12097172-B2 Prevention and treatment of diabetic nephropathy THE CHILDREN'S MEDICAL CENTER CORPORATION (US) 2024-09-24 US claimed
WO-2024146918-A1 CXCL8 INHIBITORS FOR USE IN THE TREATMENT OF OCULAR MUCOUS MEMBRANE PEMPHIGOID AND/OR ORAL MUCOUS MEMBRANE PEMPHIGOID DOMPE' FARMACEUTICI SPA (IT) 2024-07-11 WO claimed
EP-4397305-A1 CXCL8 INHIBITORS FOR USE IN THE TREATMENT OF OCULAR MUCOUS MEMBRANE PEMPHIGOID AND/OR ORAL MUCOUS MEMBRANE PEMPHIGOID Dompe' Farmaceutici S.P.A. (IT) 2024-07-10 EP claimed
US-20240156757-A1 CXCL8 INHIBITOR AND PHARMACEUTICAL COMPOSITION THEREOF FOR USE IN THE TREATMENT OF SEIZURES DOMPE' FARMACEUTICI SPA (IT) 2024-05-16 US claimed
US-20190224148-A1 PREVENTION AND TREATMENT OF DIABETIC NEPHROPATHY THE CHILDREN'S MEDICAL CENTER CORPORATION (US) 2019-07-25 US claimed
CN-109937037-A For treating the IL-8 inhibitor of certain urinary disorders 东佩制药股份公司 2019-06-25 CN claimed
CN-107921105-A 8 inhibitor of IL is used for the purposes for treating some urinary disorders 东佩制药股份公司 2018-04-17 CN claimed
EP-2346841-B1 2-ARYL-PROPIONIC ACIDS AND DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM DOMPÉ S P A (IT) 2015-01-14 EP claimed
US-8624036-B2 2-aryl-propionic acids and derivatives and pharmaceutical compositions containing them DOMPE S.P.A. (IT) 2014-01-07 US claimed
US-20110207785-A1 2-Aryl-Propionic Acids and Derivatives and Pharmaceutical Compositions Containing Them DOMPE S.P.A. (IT) 2011-08-25 US claimed
CN-102159558-A 2-arylpropionic acids and derivatives thereof and pharmaceutical compositions containing said compounds DOMPE SPA 2011-08-17 CN claimed
EP-2346841-A2 2-ARYL-PROPIONIC ACIDS AND DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM Dompe S.p.A. (IT) 2011-07-27 EP claimed
WO-2010031835-A2 2-ARYL-PROPIONIC ACIDS AND DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM DOMPE' S.P.A. (IT) 2010-03-25 WO claimed
EP-2166006-A1 2-aryl-propionic acids and derivatives and pharmaceutical compositions containing them Dompe' S.P.A. (IT) 2010-03-24 EP claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110207785-A1 2-Aryl-Propionic Acids and Derivatives and Pharmaceutical Compositions Containing Them CXCR3, F2RL1, FPR2 FFAR2 194/4885GAA 2803/4885NPC1 1922/4885
US-20240156757-A1 CXCL8 INHIBITOR AND PHARMACEUTICAL COMPOSITION THEREOF FOR USE IN THE TREATMENT OF SEIZURES CXCL8, CCR8, CXCL10 FFAR2 1278/4885GAA 4014/4885NPC1 3240/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.